Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy

Maxime Teisseyre; Vesna Brglez; Marion Cremoni; Céline Fernandez; Daisy Graça; Sonia Boyer-Suavet; Sylvia Benzaken; Vincent L M Esnault; Barbara Seitz-Polski

doi:10.2215/CJN.0000000000000152

Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy

Clin J Am Soc Nephrol. 2023 Jun 1;18(6):785-787. doi: 10.2215/CJN.0000000000000152. Epub 2023 Apr 17.

Authors

Maxime Teisseyre^{1

2

3}, Vesna Brglez^{1

3

4}, Marion Cremoni^{1

3

4}, Céline Fernandez^{1

3

4}, Daisy Graça^{1

3

4}, Sonia Boyer-Suavet^{1

3}, Sylvia Benzaken⁴, Vincent L M Esnault^{1

2}, Barbara Seitz-Polski^{1

2

3

4}

Affiliations

¹ Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, CHU de Nice, Université Côte d'Azur, Nice, France.
² Service de Néphrologie-Dialyse-Transplantation, CHU de Nice, Université Côte d'Azur, Nice, France.
³ Unité de Recherche Clinique Côte d'Azur (UR2CA), Université Côte d'Azur, Nice, France.
⁴ Laboratoire d'Immunologie, CHU de Nice, Université Côte d'Azur, Nice, France.

No abstract available

MeSH terms

Glomerulonephritis, Membranous* / drug therapy
Humans
Immunologic Factors
Immunosuppressive Agents
Receptors, Phospholipase A2
Risk Factors
Rituximab / therapeutic use

Substances

Rituximab
Immunologic Factors
Immunosuppressive Agents
Receptors, Phospholipase A2